Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.123.267044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Angela Collarino und 16 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
This study investigated whether radiomic features extracted from pretreatment [18F]FDG PET could improve the prediction of both histopathologic tumor response and survival in patients with locally advanced cervical cancer (LACC) treated with neoadjuvant chemoradiotherapy followed by surgery compared with conventional PET parameters and histopathologic features.
Methods
The medical records of all consecutive patients with LACC referred between July 2010 and July 2016 were reviewed. [18F]FDG PET/CT was performed before neoadjuvant chemoradiotherapy. Radiomic features were extracted from the primary tumor volumes delineated semiautomatically on the PET images and reduced by factor analysis. A receiver-operating-characteristic analysis was performed, and conventional and radiomic features were dichotomized with Liu's method according to pathologic response (pR) and cancer-specific death. According to the study protocol, only areas under the curve of more than 0.70 were selected for further analysis, including logistic regression analysis for response prediction and Cox regression analysis for survival prediction.
Results
A total of 195 patients fulfilled the inclusion criteria. At pathologic evaluation after surgery, 131 patients (67.2%) had no or microscopic (≤3 mm) residual tumor (pR0 or pR1, respectively); 64 patients (32.8%) had macroscopic residual tumor (>3 mm, pR2). With a median follow-up of 76.0 mo (95% CI, 70.7-78.7 mo), 31.3% of patients had recurrence or progression and 20.0% died of the disease. Among conventional PET parameters, SUVmean significantly differed between pathologic responders and nonresponders. Among radiomic features, 1 shape and 3 textural features significantly differed between pathologic responders and nonresponders. Three radiomic features significantly differed between presence and absence of recurrence or progression and between presence and absence of cancer-specific death. Areas under the curve were less than 0.70 for all parameters; thus, univariate and multivariate regression analyses were not performed.
Conclusion
In a large series of patients with LACC treated with neoadjuvant chemoradiotherapy followed by surgery, PET radiomic features could not predict histopathologic tumor response and survival. It is crucial to further explore the biologic mechanism underlying imaging-derived parameters and plan a large, prospective, multicenter study with standardized protocols for all phases of the process of radiomic analysis to validate radiomics before its use in clinical routine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
- Section of Nuclear Medicine, University Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, Rome, Italy.
- Research Core Facility Data Collection G-STeP, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
- Institute of Neuroscience and Medicine, INM-4, Forschungszentrum Jülich GmbH, Jülich, Germany.
- PET/CT Center, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
- Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy.
Zitieren
APA
Collarino, A., Feudo, V., Pasciuto, T., Florit, A., Pfaehler, E., de Summa, M., Bizzarri, N., Annunziata, S., Zannoni, G. F., de Geus-Oei, L. F., Ferrandina, G., Gambacorta, M. A., Scambia, G., Boellaard, R., Sala, E., Rufini, V., & van Velden, F. H. (2024). Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.267044
Vancouver
Collarino A, Feudo V, Pasciuto T, Florit A, Pfaehler E, de Summa M, et al. Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.267044
BibTeX
@article{Collarino2024,
author = {Collarino, Angela and Feudo, Vanessa and Pasciuto, Tina and Florit, Anita and Pfaehler, Elisabeth and de Summa, Marco and Bizzarri, Nicolò and Annunziata, Salvatore and Zannoni, Gian Franco and de Geus-Oei, Lioe-Fee and Ferrandina, Gabriella and Gambacorta, Maria Antonietta and Scambia, Giovanni and Boellaard, Ronald and Sala, Evis and Rufini, Vittoria and van Velden, Floris Hp},
title = {Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer?},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.123.267044}
}
EUVIMED